纪要涉及的公司 Senti Biosciences (SNTI)，一家专注于用逻辑门控技术改变肿瘤治疗方式的公司，在纳斯达克上市 [3][4] 纪要提到的核心观点和论据 公司技术优势 - 逻辑门控技术可针对无单一明确靶点的癌症适应症，能识别癌细胞上的多个抗原并杀伤，同时识别健康细胞抗原并保护，与市场上其他ADC、T细胞衔接器或CAR - T细胞疗法有差异化 [4][35] - 已开发出四类基因电路技术，可应用于任何细胞或基因治疗产品，包括逻辑门控概念、多臂工程、调节器拨盘和合成启动子库 [6][37] 核心产品SENTY202 - **产品设计**：是一款现货型CAR - NK项目，针对AML的两个靶点CD33和FLT3，通过识别EMCN保护健康造血干细胞；产品源自健康成人捐赠者的PBMCs提取的NK细胞，用含三个基因的逆转录病毒载体转导 [4][13][35] - **临床数据**：在复发难治性AML患者群体中开展试验，7例有可报告数据的患者中，5例达到ORR反应，4例达到复合CR反应（包括初步RP2D队列中2/3），所有CR患者均达到MRD阴性状态，且反应持续时间为4 - 8个月以上且仍在继续 [5][11][36] - **安全性**：安全性良好，可在门诊环境招募患者，未检测到重大剂量限制性毒性（DLTs），并根据部分数据确定了初步RP2D [11][43] - **作用机制验证**：通过详细的CyTOF数据和Cytop分析，发现产品能减少骨髓中的白血病干细胞数量，同时维持或增加造血干细胞数量，反映在患者外周血细胞计数的恢复上 [12][53] - **药代动力学**：PK曲线与同种异体NK细胞疗法和其他同种异体细胞一致，细胞在约14天内可检测到，免疫重建后细胞数量下降 [25][57] 市场需求和挑战 - AML是难治疗的血液癌症，美国每年新诊断患者超2万例，复发难治性患者的CR率为15 - 25%，中位生存期约5个月；疾病异质性高，且已知的AML靶点也在健康细胞上表达，单一靶点治疗毒性大、治疗窗口有限 [9][41] 未来发展方向 - 扩大SENTY202在其他患者群体的应用，如MDS、儿科或早期AML患者 [27][58] - 利用逻辑门控技术拓展到其他细胞疗法，尤其是实体瘤治疗，已开始挖掘相关适应症并开发项目 [27][59] 其他重要但是可能被忽略的内容 - 公司在2024年12月获得NEA、Celadon Partners、Bayer Leaps等机构的投资，支持SENTY202的临床研究和推向市场 [33][65] - 公司团队成员经验丰富，如总裁Kanye Rajangam在细胞治疗产品开发方面经验丰富，还有曾参与Kite Gilead公司Kite CAR - T产品扩大规模的人员加入 [33][66] - SENTY202有两种剂量水平（10亿细胞/剂量和15亿细胞/剂量）和两种给药方案，患者可接受多周期治疗，包括缓解后的巩固周期 [16][48] - 评估MRD阴性状态通过当地站点进行，部分站点使用NGS，部分使用流式细胞术，流式细胞术灵敏度约为10⁻⁴ [20][51]

Video illustrates SENTI-202’s MoA, namely to selectively kill both AML blasts and leukemic stem cells (LSCs) while protecting healthy hematopoietic stem cells/ hematopoietic stem and progenitor cells (HSC/HSPCs) using its novel CD33 OR FLT3 NOT EMCN Logic-Gated gene circuitAccess video here SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period from ___to___ Commission File Number 001-40440 Senti Biosciences, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorp ...

财务数据关键指标变化 - 截至2025年3月31日，公司持有现金及现金等价物约3380万美元[10] - 2025年和2024年第一季度研发费用分别为930万美元和880万美元，增加50万美元[10] - 2025年和2024年第一季度一般及行政费用分别为710万美元和750万美元，减少40万美元[14] - 2025年第一季度净亏损1410万美元，摊薄后每股亏损1.41美元[14] SENTI - 202业务线数据关键指标变化 - 9例复发或难治性AML患者接受SENTI - 202不同剂量治疗，7例可评估总体反应[3] - 初步推荐的2期剂量（RP2D）为1.5 x 10⁹个CAR NK细胞，在28天周期的第0、7、14天给药[3] - 初步RP2D队列中3例患者有2例实现复合完全缓解（cCR）[3] - 7例可评估总体反应患者中5例达到客观缓解率（ORR），4例达到cCR [3] - 4例cCR患者经评估均为微小残留病阴性（MRD -）[3] SENTI - 301A/SN301A业务线数据关键指标变化 - SENTI - 301A/SN301A因观察到剂量限制性毒性，停止在中国单中心研究者发起试验的入组[11] 前瞻性陈述相关 - 新闻稿和文件包含前瞻性陈述，涉及公司增长、临床试验等预期[17] - 诸多因素可能导致实际结果与前瞻性陈述有重大差异，如国内外环境、行业竞争等[18] 信息获取与投资者联系 - 可通过公司网站、X和领英获取更多信息[19] - 投资者可联系JTC Team, LLC的Jenene Thomas，电话(908) 824 - 0775，邮箱SNTI@jtcir.com[20]

Positive Phase 1 data from lead program, SENTI-202, recently presented at the AACR Annual Meeting: SENTI-202 was generally well tolerated, preliminary RP2D identified; 4 of 7 patients achieved composite Complete Remission (cCR) (3 CR, 1CRh), all 4 cCR patients were measurable residual disease (MRD) negative as assessed by local standard of care;All cCR patients maintaining responses, from 4+ to 8+ months ongoing Ongoing enrollment in Phase 1 SENTI-202 study to confirm the preliminary recommended Phase 2 do ...

NEW YORK, May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Senti Biosciences, Inc. ("Senti" or the "Company") (NASDAQ: SNTI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Senti and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On April 28, 2025, Senti ...

NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc. (“Senti” or the “Company”) (NASDAQ: SNTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Senti and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On April 28, 2 ...

Kanya Rajangam, MD, PhD, President, Head of R&D and Chief Medical Officer of Senti Bio discusses the positive data from lead program, SENTI-202, recently presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 Watch the “What This Means” segment here SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its ...

Live video webcast presentation on Thursday, May 8th at 1:00 PM ET Presentation will highlight the recently announced positive preliminary clinical results of lead program, SENTI-202, in the treatment of patients with Relapsed/Refractory AML SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, ...

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Senti Biosciences, Inc. (“Senti” or the “Company”) (NASDAQ: SNTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Senti and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On April 28 ...